Vascular Targeting Combined With Radiosurgery In An Arteriovenous Malformation Rat Model
Funder
National Health and Medical Research Council
Funding Amount
$102,345.00
Summary
Cerebral arteriovenous malformations are an important cause of stroke and brain bleeds. In many patients such a stroke can result in severe disability or death. Current management involves a combination of surgery, radiation therapy and endovascular treatments and carry a high risk of complications. This research project suggests a new form of treatment whereby irradiating the vascular malformation a medication could be administered to cause targeted clotting of the malformation.
The Role Of Tissue Factor Pathway Inhibitor (TFPI) In The Pathogenesis Of Lymphatic Malformations
Funder
National Health and Medical Research Council
Funding Amount
$87,198.00
Summary
Lymphatic malformations or cystic hygomas are growths of abnormal blood vessels called 'lymphatic vessels'. They are present at birth, commonly affect the head and neck, and can cause lifelong problems due to growth in size and frequent infections. Surgical treatment does not offer a cure, and problems often persist lifelong. The finding that blood clots are continuously forming and breaking down in these growths may provide a clue to relieving symptoms and understanding the cause of this condit ....Lymphatic malformations or cystic hygomas are growths of abnormal blood vessels called 'lymphatic vessels'. They are present at birth, commonly affect the head and neck, and can cause lifelong problems due to growth in size and frequent infections. Surgical treatment does not offer a cure, and problems often persist lifelong. The finding that blood clots are continuously forming and breaking down in these growths may provide a clue to relieving symptoms and understanding the cause of this condition.Read moreRead less
Childhood Lymphatic Malformations: The Mechanism Of Rapamycin In Controlling Growth
Funder
National Health and Medical Research Council
Funding Amount
$456,579.00
Summary
Lymphatic malformations (also known as cystic hygromas or lymphangiomas) cause deformity and pain which can last lifelong. Current treatments help but do not fix all the symptoms. Rapamycin, a drug used for many years in children and adults with kidney transplants, may be useful for treating children with lymphatic malformations. We aim to understand how the drug works on the cells of lymphatic malformations in culture and in an animal model, to develop new and more effective treatments.
Intelligent Freeform Bio-fabrication for Customised Anatomical Structures for Reconstructive Surgery. This project contributes towards the ARC priority goal on advanced materials and frontier technologies by developing an intelligent freeform biofabrication facility to produce accurate anatomical biocompatible replica structures and implants for reconstructive surgery. The products, produced from patient's CT or MRI scan data, will contribute to complex surgical procedure planning and patient ed ....Intelligent Freeform Bio-fabrication for Customised Anatomical Structures for Reconstructive Surgery. This project contributes towards the ARC priority goal on advanced materials and frontier technologies by developing an intelligent freeform biofabrication facility to produce accurate anatomical biocompatible replica structures and implants for reconstructive surgery. The products, produced from patient's CT or MRI scan data, will contribute to complex surgical procedure planning and patient education. The proposed facility will be based on multifunctional freeform fabrication process supported by intelligent software tools and database of biocompatible materials. The prospective outcomes are likely to have an excellent commercial and patenting potential that may help Australia become a leader in biomanufacturing technology.Read moreRead less
Tissue distraction: A novel approach to enhance tissue growth for soft tissue engineering purposes. This project will provide new tissues for the expanding field of regenerative medicine to treat numerous tissue defects and
1.Benefit the health & economic well being of Australian society by rapidly supplying organs and tissues.
2.Benefit the academic community by a multidisciplinary approach, involving several academic Institutions in the fields of surgery, tissue engineering, physiology, morph ....Tissue distraction: A novel approach to enhance tissue growth for soft tissue engineering purposes. This project will provide new tissues for the expanding field of regenerative medicine to treat numerous tissue defects and
1.Benefit the health & economic well being of Australian society by rapidly supplying organs and tissues.
2.Benefit the academic community by a multidisciplinary approach, involving several academic Institutions in the fields of surgery, tissue engineering, physiology, morphology, polymer chemistry & biomolecular engineering that will produce basic scientific data with a practical application. Post-graduate students and staff will train & gain significant knowledge in this area.
3. Benefit industry through new product development and IP. This project advances a platform technology with multiple applications.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120100402
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
The effectiveness of intervention in communication and safety climate in the operating room. This project will evaluate the effectiveness of an educational intervention on teamwork behaviours in surgery. It will deliver beneficial effects for communication in service delivery, safety and patient care in support of health care in high risk environments.
Interaction Of Angiotensin II And PPARg In Aortic Aneurysm Formation
Funder
National Health and Medical Research Council
Funding Amount
$427,398.00
Summary
Between 5% to 10% of men and 1% of women over the age of 60 years develop weakening of their main abdominal artery leading to slow dilation of the vessel. If this process continues long term the artery can burst resulting in sudden death. At present the only treatment available for this problem is surgery, either open or minimally invasive. Both these forms of treatment are associated with significant complications and unsuitable for some patients. Thus the development of a drug treatment which ....Between 5% to 10% of men and 1% of women over the age of 60 years develop weakening of their main abdominal artery leading to slow dilation of the vessel. If this process continues long term the artery can burst resulting in sudden death. At present the only treatment available for this problem is surgery, either open or minimally invasive. Both these forms of treatment are associated with significant complications and unsuitable for some patients. Thus the development of a drug treatment which can slow or halt the weakening and dilation of the aorta would have great patient benefits. We have identified an important role for a newly discovered protein in weakening of the abdominal aorta. In this study we investigate the role of a pathway which appears to be fundamental in generating this protein. In particular we will assess the role of drug treatment in blocking this pathway as a basis for medical treatment for artery weakening.Read moreRead less
Randomised Controlled Trials Of Laparoscopic Techniques For Antireflux Surgery
Funder
National Health and Medical Research Council
Funding Amount
$1,031,381.00
Summary
Gastro-oesophageal reflux is common, with approximately 10% of Australians now using medication to control symptoms. Many Australians will need this medication for life, unless they undergo surgery. The cost of treating reflux is growing. Since 1992 the annual growth rate of the Pharmaceutical Benefits Scheme expenditure on reflux medication has been 13%, and the annual cost for the treatment of reflux now exceeds $1 billion. Not all patients with reflux are satisfied with medication, as some co ....Gastro-oesophageal reflux is common, with approximately 10% of Australians now using medication to control symptoms. Many Australians will need this medication for life, unless they undergo surgery. The cost of treating reflux is growing. Since 1992 the annual growth rate of the Pharmaceutical Benefits Scheme expenditure on reflux medication has been 13%, and the annual cost for the treatment of reflux now exceeds $1 billion. Not all patients with reflux are satisfied with medication, as some continue to experience symptoms. Surgery is the only treatment which will cure reflux. It has a clear role in the treatment of patients with ongoing symptoms, those who don t want to take tablets, and patients with a large hiatus hernia in whom symptoms occur due to the relocation of the stomach from the abdomen into the chest. Approximately 5,000 Australians per year undergo surgery for reflux. The standard operation achieves a good outcome in approximately 90%, although some patients are troubled by side effects. To reduce the risk of this, the original procedure has been modified. However, the evidence supporting modifications has until recently been limited. The best way to compare different operations is in randomised trials. The majority of the largest and best trials addressing this area have been undertaken in Adelaide. We have already entered 504 patients into 5 randomised trials, 4 conducted entirely in Adelaide, and one across multiple sites with the cooperation of 15 Australasian surgeons. These trials have provided a more reliable evidence base for surgeons undertaking surgery for reflux. However, long term follow-up is required to ensure that conclusions drawn are valid at late follow-up. In addition we are establishing 2 new randomised trials, which will determine how best to perform surgery for reflux, and how best to repair a large hiatus hernia. These studies will be undertaken in collaboration with more than 25 other surgeons throughout Australia.Read moreRead less